AstraZeneca’s Ultomiris®️ Cuts Proteinuria by 43.4% in Phase – 3 Trial
Alexion, AstraZeneca Rare Disease, announced positive results from a prespecified interim analysis of the global Phase III I CAN trial. The data demonstrate...
Lupin Gets U.S. FDA Approval for Ranluspec™ to Treat Retinal Disorders
Lupin Limited has secured U.S. FDA approval for Ranluspec™ (ranibizumab-hkdz), an interchangeable biosimilar to Genentech’s Lucentis® — a milestone that reshapes patient access to sight-saving biologics across...
Glenmark Launches Generic Vimpat®️ Injection in the US to Expand Injectable Portfolio
Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the official launch of its Lacosamide Injection USP, 200mg/mL,20mg/mL, 10mg/mL available in Single-Dose Vials, as detailed in the official...
Emcure and Roche Collaborate to Improve Access to Advanced Nephrology Care
Emcure Pharmaceuticals has entered into a distribution agreement with Roche India for select products in nephrology and transplantation, marking a strategic step in expanding...
India’s Lupin and Natco Pharma Secure U.S. FDA Approval for Eribulin Mesylate Injection
On 03rd June, 2026 Lupin Limited (Lupin) announced that, Lupin and its alliance partner Natco Pharma Limited (Natco) got the approval from the United States Food and Drug Administration (U.S. FDA)...
